Presentation JIM 2017 Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It Presenter: Dominick J. Angiolillo February 10, 2017
Presentation JIM 2017 Pre-treat or not to pre-treat with oral antiplatelets: This is the DUBIUS Presenter: Giuseppe Tarantini February 10, 2017
Presentation JIM 2017 The Future of Long Term Antiplatelet therapy: Is life Long Aspirin Still Necessary? Presenter: Roxana Mehran February 10, 2017
Presentation TCT 2016 Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016! Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm November 01, 2016
Presentation TCT 2016 2016 DAPT Update: Evidence and Guidelines Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla November 01, 2016
Presentation TCT 2016 Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI! Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino November 01, 2016
Presentation TCT 2016 Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies Presenter: George D. Dangas, Debabrata Mukherjee, C. Michael Gibson November 01, 2016
Presentation TCT 2016 Deciding on the Duration of DAPT Presenter: George D. Dangas, Debabrata Mukherjee, Neal S. Kleiman November 01, 2016
Presentation TCT 2016 TCT 56: Validation of PARIS Risk Scores in a Large Multi-Ethnic PCI Cohort: Results From a Large Single-Center Registry Presenter: Neal S. Kleiman, David F. Kong, Usman Baber October 31, 2016
Presentation TCT 2016 TCT 55: RiskBenefit Analysis of Upstream Antithrombotic Therapy in Patients With NonST-Segment Elevation Acute Coronary Syndromes Prior to Coronary Angiography Presenter: Neal S. Kleiman, David F. Kong, Bjorn Redfors October 31, 2016
Presentation TCT 2016 TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial Presenter: Neal S. Kleiman, David F. Kong, Didier Carrié October 31, 2016
Presentation TCT 2016 TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield October 31, 2016
Presentation TCT 2016 TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES Presenter: Dimitrios Alexopoulos, Laurent Bonello, Bjorn Redfors October 31, 2016
Presentation TCT 2016 TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events Presenter: Dimitrios Alexopoulos, Laurent Bonello, Christine Chung October 31, 2016
Presentation TCT 2016 TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber October 31, 2016
Presentation TCT 2016 TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi October 31, 2016
Presentation TCT 2016 From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished Presenter: John A. Bittl, Daniel I. Simon, Eric Van Belle October 30, 2016
Presentation TCT 2016 Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI? Presenter: John A. Bittl, Daniel I. Simon, Tullio Palmerini October 30, 2016
Presentation TCT 2016 Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys October 30, 2016
Presentation TCT 2016 If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson October 30, 2016